logo-loader
Netscientific PLC

NetScientific chief François Martelet on the 'strong return' from sale of OncoVerse

François Martelet, chief executive of the healthcare and biomedical investor Netscientific PLC (LON:NSCI) talks Proactive through the rationale behind the sale of their stake in OncoVerse LLC.

OncoVerse is a digital health platform which allows cancer patients’ care teams to collaborate and also allows clinicians across all disciplines to work together to establish the most effective treatment plan for their patients.

Quick facts: Netscientific PLC

Price: £0.07

Market: AIM
Market Cap: £5.7 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Netscientific PLC named herein, including the promotion by the Company of Netscientific PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Netscientific PLC raises £5mln to speed up portfolio commercialisation

Francois Martelet, chief executive of Netscientific PLC (LON:NSCI), caught up with Proactive's Andrew Scott following the close of their £5mln fundraise. Netscientific has a core portfolio of five companies and will use the additional funding to accelerate either the float or sale of one...

on 12/4/18

2 min read